Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.
The inside story on a campaign for the ages, as told by the individuals who worked on it.
Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.
Five decades ago, pharmaceuticals were the protected province of health professionals. Today we have DTC ads, the internet, and pharmacy handouts.
Patients who ask for a prescription after seeing an ad are more likely to get one; Mylan's executive pay is now under scrutiny
Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes
Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck's Keytruda takes the lead in first-line cancer
Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.
A new bill exempting CME reporting gains physician support; NYT op-ed calls Opdivo DTC ad "misleading;" Valeant to sell non-core assets worth $8 billion
Physicians debate DTC tax write-off; Novo Nordisk's Victoza shows 13% benefit in reducing cardiovascular risks; Shire to acquire Pfizer bowel drug
Pharma companies took issue with the methodology for the FDA's proposed studies of advertising tactics.
Pfizer buys Anacor; Harvard Medical School loosens rules for faculty ties to pharma; Vermont poised to pass price transparency bill
Advertising lobbyist said eliminating the DTC ad tax deduction is a real threat to the industry.
The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
Following print's best year since 2011, it's time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.
The launch this week of the first DTC campaign for Viberzi follows a wave of direct-to-consumer campaigns focused on promoting treatments for the two types of IBS.
After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.
One side effect (pun super-deliberately intended) of prompting pharma creatives to come up with new go-to visuals is that, well, not every idea or execution is a keeper.
Great DTC pharma advertising during the last year or so has been "sparse," says SSCG Media Group president Debbie Renner. Still, here are her top 10 picks for 2015.
Drugmakers spent 20% more on DTC ads in 2015 than in 2014. Eli Lilly was the top spender, shelling out $220.4 million to promote Cialis, its erectile dysfunction drug.
DTC is facing a new test from physicians and politicians. Here's why critics fear a deluge, and how they're pushing back.
The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.
Experts say DTC spending is a waste; Alder BioPharma's migraine drug meets study goal; sources tell Stat that execs are leaving Verily Life Sciences
The agency has proposed two studies to investigate the use of superimposed text and the use of animated characters.
The division, dubbed Omnicom Health Group, claims to serve 70% of the top 100 pharma brands.
Lawmaker seeks to stop DTC ads for newly approved drugs; testosterone therapy helps sexual function; the FDA requests more data about Catalyst's rare drug
Tapping celebrities for brand or awareness campaigns ensures a high degree of attention, but such arrangements come with concerns that "regular" ones do not.
We present to you our picks for the best and worst moments in celebrity healthcare spokespersonship—plus a few more that, frankly, we can't find anywhere.
DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.
The drugmaker's CEO said the campaign helps dispel pessimism created from a history of cancer drugs that lack "significant value."
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Sunovion hires former BI exec as VP of marketing
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy